Equibles does not estimate personal net worth.
Get an email with a short summary when Pacific Biosciences Of California, Inc. publishes a filing, an earnings call transcript or a press release.
Get PACB alertsChristian Henry is recorded as CFO at Pacific Biosciences Of California, Inc. (PACB) since December 6, 2024, Board Member at Pacific Biosciences Of California, Inc. (PACB) since January 1, 2018, CEO at Pacific Biosciences Of California, Inc. (PACB) and Chairman at Wave Life Sciences, Inc. (WVE). The newest filing on record that lists Christian Henry as Chairman at Wave Life Sciences, Inc. (WVE) is dated June 26, 2023. Pacific Biosciences Of California, Inc. reported in an 8-K filed December 6, 2024 that Christian Henry was appointed interim Chief Financial Officer, effective December 6, 2024. Christian Henry has spoken on 24 earnings calls across 1 company, most recently for Pacific Biosciences Of California, Inc. on August 5, 2026. Pacific Biosciences Of California, Inc. is classified in the Medical Devices industry within the Healthcare sector. Wave Life Sciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Pacific Biosciences Of California, Inc. includes Mark Van Oene (CEO, CFO, COO and Board Member), Christian O. Henry (Chairman and Board Member), John F. Milligan (Chairman and Board Member) and 7 others.
“On December 5, 2024, the Board of Directors of Pacific Biosciences of California, Inc. (the "Company") appointed Christian Henry, the Company's President and Chief Executive Officer, to the role of interim Chief Financial Officer and designated him as the Company's principal financial officer, effective upon the resignation of Susan G. Kim as the Company's Chief Financial Officer and principal financial officer on December 6, 2024.”
“Earlier today, we announced that I am stepping down as President and Chief Executive Officer of PacBio, and that Mark Van Owen will lead the company as President and Chief Executive Officer effective immediately.”
“Our first quarter of 2026 was highlighted by record consumable revenue, greater than 100% year-over-year growth in consumable shipments to clinically focused accounts and significant progress on our strategic objectives, including entering our first significant AI-related project with Basecamp Research.”
“Our fourth quarter results exceeded expectations and were highlighted by all-time record consumable revenue and strong instrument placements for both the Revio and the Vega platforms.”
“Starting with our top line performance in the third quarter, revenue came in at slightly below our expectations at $38.4 million, primarily due to fewer than expected Vega shipments in Europe and lower than expected revenue on ASPs.”
“Our financial results in the second quarter demonstrate that we continue to make significant progress towards our goal of increasing the adoption of our long-read sequencing platforms and driving the company towards positive cash flows.”
2024-12-06–present
2018-01-01–present
Start not stated–present
Last confirmed June 26, 2023
Proxy statement
Start not stated–present
Last confirmed October 14, 2026
Medical Devices · Healthcare
CEO, CFO, Board Member
2018-01-01–present
